R&D channel feed – Endpoints News

R&D channel feed

Exhibit A in Valeant’s blockbuster R&D boast runs into trouble at the FDA

9 years ago

What’s the hottest biotech R&D field in venture investing?

9 years ago

Rhythm eyes a pivotal test after rolling through PhII with upbeat results for rare obesity cases

9 years ago

With biosimilars gaining momentum, Amgen and Allergan cite success of Herceptin's copycat

9 years ago

The Scangos legacy: A blockbuster MS record with lingering doubts about the pipeline

9 years ago

Sidelined at the FDA, AstraZeneca watches as new team seizes rival drug in $1.5B Relypsa buyout

9 years ago

New CEO Szela cuts Aegerion staff again, pulls Juxtapid out of the EU

9 years ago

Merck is scouting sites for a new research hub in the Bay Area, plans new hires

9 years ago

AstraZeneca culls its neuroscience team, exits Kendall Square office

9 years ago

By the numbers: 2-year tally of Celgene's biotech partnership deals tops $3B in cash

9 years ago

AveXis wins the inside track at the FDA with gene therapy ‘breakthrough’

9 years ago

Synthorx lines up some big synthetic biology R&D goals after grabbing a $10M round

9 years ago

Beleaguered Zafgen crushed after FDA demands force it to dump lead drug

9 years ago

Valeant wins first round in $445M gamble on brodalumab approval

9 years ago

Merck KGaA blueprints a $115M 'collaboration campus' for Massachusetts

9 years ago

Merck-backed Quartet places biotech vet Gerhard Koenig at the helm

9 years ago

Celgene signs Jounce as its new biotech star in $2.6B ‘immuno-oncology 2.0’ pact

9 years ago

Celgene EVP Bagger gets a plum assignment on Trump team

9 years ago

Biotech vet Gould lands $55M startup round for a new Third Rock platform biotech

9 years ago

Novartis’ campaign to sweep biosimilar approvals hits a setback

9 years ago

Brainstorm’s rally fizzles after investors turn sour on questionable ALS data

9 years ago

Playing defense, Roche loses megafranchise gambit as Gazyva flunks head-to-head with Rituxan

9 years ago

With cash running low, little Evoke loses a crucial PhIII gamble

9 years ago

Which big biopharma companies put R&D as their top priority?

9 years ago

First page Previous page 326 327 328329330 331 332 Next page Last page